In combination with cisplatin, an increase in the expression of PD-1 and PD-L1 in tumors, coupled to a strong sensitization of NSCLC to checkpoint inhibitors (CPI) could be detected (14). Here, CD274 is linked to non-small cell lung carcinoma.